Future research directions may focus on an evaluation of an alternative of use of TRT in subjects with diabetes, even defining different daytime to take this therapy, depending by glycemic values of the subjects, leading to a "tailor made" treatment. Finally, the increase in total testosterone after 12 weeks appeared rather moderate, and this may have influenced the outcome; this could be due to the phenotypic features of our population, characterized by overweight/obesity and mainly hypogonadotropic hypogonadism. In addition, a long-term real-world evidence study showed that TRT with undecanoate injections promoted the remission of DM in one-third of the patients and the improvement of glycemic control in the remaining subjects . We clearly are seeing many more people who are taking high levels of testosterone in gel form because they tell themselves it’s one dose and they apply it all over. Potential mechanisms include resistance to the normal stimulatory effects of insulin on the hypothalamic-pituitary-gonadal axis, suppression by pro-inflammatory cytokines, and high leptin levels. Reassuringly, there was no evidence of an increased risk of cardiovascular disease, although a slight increased risk of venous thromboembolism and atrial fibrillation was observed. The use of validated questionnaires is not currently recommended to either define which patients are candidates for testosterone therapy or to monitor symptom response in patients on testosterone therapy. Clinicians should use a total testosterone level below 300 ng/dL as a reasonable cut-off in support of the diagnosis of low testosterone. Given the clinical and commercial testosterone landscape, the American Urological Association (AUA) identified a need to produce an evidence-based document that informs clinicians on the proper assessment and management of patients with testosterone deficiency. Our results demonstrate that hypogonadal T2DM patients who underwent long-term testosterone replacement therapy experienced a sustained remission of their diabetes. Clinicians can use this information to assess the possible hazards and advantages of testosterone therapy for their patients. Strong Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is substantial. Alternative testosterone therapies included SERMs, hCG, and AIs. Minimal data were found regarding outcomes of frailty, risk of venous thromboembolism, hyperestrogenemia, sleep apnea, prostate biopsy, recurrence of treated prostate cancer, and incidence of breast cancer. The searches included Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Another study looked at men with metabolic syndrome, a condition that includes insulin resistance, high blood sugar, and low testosterone. In some cases, their blood sugar levels dropped enough that they needed less medication to manage their diabetes. For example, one study found that men with type 2 diabetes and low T who received TRT had better blood sugar control after treatment. This means that after getting TRT, their bodies use insulin more effectively, leading to lower blood sugar levels. As a result, people with low T often have higher blood sugar levels, which can worsen diabetes. Individual study factors, such as the heterogeneity and demographics of the study population, the comorbidities of the study population and how they are controlled in the analysis, and confidence intervals also impact overall study quality. When reviewing results from meta-analyses, it is important to recognize that the overall reliability is dependent on the quality of the weakest study included in the analysis. To accurately interpret the published testosterone literature, it is important to critically evaluate various aspects of study design, including the population evaluated, study inclusion/exclusion criteria, duration of follow-up, primary endpoints, adverse event reporting, statistical reporting, and clinical relevance of findings. Please refer to Table 7 below for a summary of follow-up testing for men being treated for testosterone deficiency. Patients on short-acting IM or short-acting SQ pellets (testosterone cypionate or enanthate) should have their testosterone measured after several cycles such that testosterone level equilibration has been achieved. Given the mechanisms of action of anastrozole, clomiphene citrate, and hCG, patients using these medications should wait a longer period before follow-up blood work is performed. The impact of testosterone therapy on QoL in men with testosterone deficiency is challenging to quantify due to variable study methodology and inherent limitations with standardized questionnaires. Despite the absence of definitive evidence, the Panel recommends that patients with these symptoms be counseled regarding the possibility of improvement on testosterone therapy. Studies reporting optimal testosterone levels yielded a mean 2.2 kg increase in lean body mass compared to a non-significant 0.8 kg increase when suboptimal levels of testosterone were achieved.
